Fact Checked
Fact Checked
This article has been fact checked by a licensed expert before publication to ensure all information provided is correct and safe.
Can taking weight loss injections lower your risk of getting dementia?
Weight loss injections like Wegovy contain GLP-1 receptor agonists (GLP-1 RAs), which show promising results for brain health. Research shows that GLP-1 RAs can protect brain cells, improve blood flow to the brain, and possibly slow disease progression.
Although GLP-1 RAs aren’t approved for dementia, emerging research shows their therapeutic potential for neurodegenerative diseases.
Medically reviewed by
Alexandra Cristina Cowell, Writer & Clinical Content Reviewer
Table of contents
Medically reviewed by
Dr Alexandra Cristina Cowell
Writer & Clinical Content Reviewer
on May 02, 2025.
Meet Alexandra Cristina
Last updated on May 02, 2025.
Was this article useful?
Summary
- GLP-1 RA drugs may protect the brain, reduce inflammation, and slow dementia-related disease progression.
- In Alzheimer’s, GLP-1 RAs may reduce amyloid plaques, support neurons, and ease symptoms.
- In Parkinson’s disease, these drugs may protect dopamine-producing neurons and improve motor function, though evidence is still limited and inconclusive
- GLP-1s aren't approved for dementia yet, but research suggests strong potential for future use in brain health.
How can weight loss injections help with neurodegenerative diseases?
Neurodegenerative diseases (ND) like Alzheimer’s and Parkinson’s disease affect your nerve cells, often leading to a decline in cognitive function. There’s no cure for these diseases, instead, treatments aim to slow disease progression and improve quality of life.
Weight loss injections (like Wegovy, Saxenda and Zepbound) have been in the spotlight for their weight loss results and proven ability to manage blood sugar levels. They mimic the hormone GLP-1, which your body naturally releases after eating to signal your brain that you’re full and satisfied.
In addition to weight loss, recent research shows GLP-1’s neuroprotective properties might be able to prevent nerve cell damage and death.
How GLP-1s help with insulin resistance
Insulin resistance is when your body doesn’t respond to insulin effectively, which leads to uncontrolled blood sugar levels and the development of type 2 diabetes.
But more than this, insulin resistance can damage your brain too, contributing to ND. Your brain needs insulin to create new neuronal connections to support memory and learning, and without it, inflammation can increase, damaging neurons, affecting your memory and ability to function.
GLP-1 RAs can enhance insulin sensitivity, which may improve cognitive function. It also has anti-inflammatory properties that may help reduce brain inflammation and slow the progression of ND.
How GLP-1s could help neuronal survival
GLP-1 has been shown to have neuroprotective properties, including:
- Reducing nerve cell death, which prevents cognitive decline.
- Promoting the growth of neurons to help build new connections.
- Improving motor and sensory function.
- Decreasing brain inflammation.
- Increasing blood flow to the brain to provide essential nutrients and oxygen.
These mechanisms may help neurons survive and improve overall brain function. As a result, GLP-1 agonist medications may also help to bring about these benefits (by performing the same functions within your body).
How GLP-1s help neuronal inflammation
Brain inflammation plays a key role in the development of ND. Although inflammation can be a neuroprotective property, chronic inflammation can cause neuronal damage and death.
Brain inflammation is believed to be caused by amyloid plaques, which are a hallmark of Alzheimer’s disease (AD).
Studies show that GLP-1 has anti-inflammatory effects, reduces the accumulation of amyloid plaque, and enhances memory function.
How can weight loss injections help Alzheimer's disease?
Alzheimer’s disease (AD) is the most common type of dementia. In Canada, it’s estimated that over 747,000 people are living with Alzheimer’s or another dementia. The symptoms may include poor judgment, difficulty with thinking, memory issues, confusion and personality changes. There’s no cure for AD, but treatments can slow the progression.
Although this hasn’t been proven in humans yet, GLP-1 RA may reduce the buildup of amyloid plaques – harmful clumps of protein in the brain that are strongly linked to Alzheimer’s.
Weight loss injections reduce amyloid plaques and tau tangles
AD is characterized by amyloid plaques, which are a buildup of amyloid protein in the brain. This build-up can disrupt neural communication, increase inflammation and damage nerve cells.
Tau tangles are the build-up of the tau protein inside the nerve cell, which can lead to neuron death. These also play a significant role in AD and can cause cognitive decline.
GLP-1 RA may reduce the buildup of amyloid plaques and tau tangles, helping prevent neuron damage and death. GLP-1 RA may also promote the growth of new neurons, helping improve symptoms and slow disease progression.
While studies have shown promising results, one downside of taking GLP-1 RA as an AD patient is being underweight. The appetite-suppressing properties of GLP-1 RA can lead to serious health issues like nutrient deficiencies.
How can weight loss injections help Parkinson’s disease?
Parkinson’s disease (PD) is a neurodegenerative disorder that primarily affects motor skills, such as movement and balance. It’s caused by a loss of nerve cells that produce dopamine, causing motor-related symptoms like slow movements, rigidity, and tremors. As the disease worsens, it can lead to non-motor symptoms like depression, anxiety, sleep issues, and memory problems, and many people with Parkinson’s eventually develop dementia.
Some studies have shown GLP-1 RA can restore dopamine levels, which may reverse the effects of PD and reduce symptoms.
Weight loss injections protect the dopaminergic neurons
Recent research shows GLP-1 RA may restore dopamine levels, which can help improve motor and non-motor related symptoms. Its neuroprotective properties may prevent further degradation of nerve cells that produce dopamine.
GLP-1 RAs effect on PD is inconclusive; some studies show promising results while others show no significant improvement in symptoms.
It’s important to note that most studies have a small sample size, so more research would be needed to investigate the relationship between GLP-1 RA and PD.
How can weight loss injections help reduce the risk of vascular dementia?
Improved vascular health
Reduced blood flow to the brain deprives it of essential nutrients and oxygen needed for it to function properly. This deprivation can cause the brain cells to become damaged.
Research suggests that GLP-1 RA’s may help improve blood flow to the brain by relaxing and widening blood vessels. This increased blood flow can help deliver more oxygen and nutrients to brain tissue, which might help with symptoms of vascular dementia.
Additionally, since strokes are a major cause of vascular dementia, using a GLP-1 RA after a stroke could possibly reduce brain damage and potentially lower the risk of developing vascular dementia.
GLP-1 RA can also help manage blood pressure, blood sugar and total cholesterol level – all important for brain and heart health.
Improved mitochondrial function
Mitochondria are an important component in a cell that produces energy. Studies show mitochondrial dysfunction can increase oxidative stress, impair energy levels and affect neuronal cells, which all contribute to the development of vascular dementia.
GLP-1 RA may reduce oxidative stress, helping prevent damage and death of neuronal cells. It may also restore mitochondrial function and improve blood flow to the brain, further improving symptoms.
Could weight loss injections be used to help neurodegenerative diseases in the future?
GLP-1 RA may be used to treat and prevent neurodegenerative diseases. But not all GLP-1 RAs have the same benefit; the results can vary depending on the specific type of GLP-1 RA used.
While more research is needed, GLP-1 RA shows exciting potential to improve brain health and lower the risk of dementia.
Reference Popover #ref1
Treated trusted source
Fessel, J. (2024).
All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others. Journal of Clinical Medicine, 13(13), 3729.
Reference Popover #ref2
Treated trusted source
Yoon, J. H., et al. (2023).
How Can Insulin Resistance Cause Alzheimer’s Disease? International Journal of Molecular Sciences, 24(4), 3506.
Reference Popover #ref3
Treated trusted source
Talbot, K. (2014).
Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs. Neurodegenerative Disease Management, 4(1), 31.
Reference Popover #ref4
Treated trusted source
Yang, X., et al. (2022).
Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research. Frontiers in Neurology, 13, 844697.
Reference Popover #ref5
Treated trusted source
Kinney, J. W., et al. (2018).
Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 4, 575.
Reference Popover #ref6
Treated trusted source
Nowell, J., Blunt, E., & Edison, P. (2023).
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease. Molecular Psychiatry, 28(1), 217-229.
Reference Popover #ref7
Treated trusted source
alz.org (2019).
Alzheimer’s & Dementia Help | Canada | Alzheimer’s Association. Alzheimer’s Association.
Reference Popover #ref8
Treated trusted source
Kalinderi, K., Papaliagkas, V., & Fidani, L. (2024).
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. International Journal of Molecular Sciences, 25(7), 3812.
Reference Popover #ref9
Treated trusted source
Shereen Nizari, Basalay, M., et al. (2021).
Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. Basic Research in Cardiology, 116(1).
Reference Popover #ref10
Treated trusted source
Luna-Marco, C., et al. (2023).
Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biology, 66, 102849.
Reference Popover #ref11
Treated trusted source
Au, H.C.T., et al. (2025).
Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders. Neuroscience & Biobehavioral Reviews, 173, p.106159.
Reference Popover #ref12
Treated trusted source
Åström, D.O., et al. (2022).
High risk of developing dementia in Parkinson’s disease: a Swedish registry-based study. Scientific Reports, 12(1), p.16759.
How we source info:
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognized analytics or data body. Read more in our editorial policy.
How can weight loss injections help with neurodegenerative diseases?
Tell us what you want to hear.
Have a subject you’d like us to cover in a future article? Let us know.
Give us the inbox treatment.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
Find treatment
I'm looking for
Popular searches:
Sign up to our newsletter for all the latest on Weight Loss and more.
By clicking ‘Subscribe now’, you agree to our terms of use